Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Forest’s LABA/LAMA Delay Gives GSK A Lengthy Lead On The Market

This article was originally published in The Pink Sheet Daily

Executive Summary

News that Forest/Almirall’s LABA/LAMA combination will be delayed due to a manufacturing issue means that GlaxoSmithKline’s Anoro Ellipta will continue to dominate the market as the sole fixed-dose combination available in the U.S.

You may also be interested in...



AstraZeneca Capitalizing On Respiratory With Actavis’ Divestiture

The British pharma is acquiring Actavis’ unwanted respiratory portfolio in a deal that will help AstraZeneca meet the $8 billion in revenues it expects to achieve from its respiratory franchise by 2023. For Actavis, it means unloading a handful of drugs that were underperforming and neglected.

Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal

Spain’s leading pharma company will use proceeds of its respiratory products sale to bulk up in dermatology, with the aim of becoming a global leader in the sector.

Boehringer’s Tiotropium Spray May Be Ready To Shed Mortality Issues

FDA Pulmonary-Allergy Drugs Advisory Committee to review NDA for COPD and will discuss safety results from trial comparing inhalation spray to powder.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS077183

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel